Need for Azacitidine featured in Daily Telegraph

The doctors have called on the Government’s drugs rationing body to give terminally ill cancer patients the drug azacitidine.

The medication treats rare cancers of the blood and bone marrow.

But the drug, also known as Vidaza, has been turned down by the National Institute for Health and Clinical Excellence (Nice).

The organisation says at a cost of around £45,000 a year the drug is not cost effective.
On average it offers terminally ill patients around an extra nine months of life.

Read the full article at Telegraph.co.uk

Free donations by shopping